Associated Papers
Genomics of cardiometabolic disease: contributions of Mexican research groups.
Domínguez-Pérez M et al.
Gaceta Medica De Mexico, 2025
Exome Sequence Data of Eight SLC Transporters Reveal That SLC22A1 and SLC22A3 Variants Alter Metformin Pharmacokinetics and Glycemic Control.
Morales-Rivera MI et al.
Pharmaceuticals (basel, Switzerland), 2024
The L125F MATE1 variant enriched in populations of Amerindian origin is associated with increased plasma levels of metformin and lactate.
Morales-Rivera MI et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2021
Lack of genomic diversity in the SLC47A1 gene within the indigenous Xhosa population.
Jacobs C et al.
Drug Metabolism and Personalized Therapy, 2016
Identification and functional characterization of novel MATE1 genetic variations in Koreans.
Kim TH et al.
Biochemical and Biophysical Research Communications, 2013
Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.
Mannino GC et al.
Molecular Diagnosis & Therapy, 2012
Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.
Lai Y et al.
Expert Opinion on Drug Metabolism & Toxicology, 2012
Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function.
Chen Y et al.
The Pharmacogenomics Journal, 2009
Select a paper to view details